Tijono, S.M.; Palmer, B.D.; Tomek, P.; Flanagan, J.U.; Henare, K.; Gamage, S.; Braun, L.; Ching, L.-M.
Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2. Pharmaceuticals 2022, 15, 1090.
https://doi.org/10.3390/ph15091090
AMA Style
Tijono SM, Palmer BD, Tomek P, Flanagan JU, Henare K, Gamage S, Braun L, Ching L-M.
Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2. Pharmaceuticals. 2022; 15(9):1090.
https://doi.org/10.3390/ph15091090
Chicago/Turabian Style
Tijono, Sofian M, Brian D. Palmer, Petr Tomek, Jack U. Flanagan, Kimiora Henare, Swarna Gamage, Lukas Braun, and Lai-Ming Ching.
2022. "Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2" Pharmaceuticals 15, no. 9: 1090.
https://doi.org/10.3390/ph15091090
APA Style
Tijono, S. M., Palmer, B. D., Tomek, P., Flanagan, J. U., Henare, K., Gamage, S., Braun, L., & Ching, L.-M.
(2022). Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2. Pharmaceuticals, 15(9), 1090.
https://doi.org/10.3390/ph15091090
